IP Library Granted Patent US 10,874,611
Granted Patent B2
US 10,874,611 · App. 16/078,406 · Granted Dec 29, 2020

Chemotactic, drug-containing polymersomes

Inventor: Giuseppe Battaglia (London, GB)
Assignee: UCL BUSINESS LTD
A61K9/1273A61K38/44A61K38/443A61K47/6915C12Y101/03004C12Y111/01006Y10S977/773Y10S977/906
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,874,611
App. No.
16/078,406
Granted
Dec 29, 2020
Kind
B2
Abstract

The present invention relates to polymersomes that contain an encapsulated drug and that exhibit chemotaxis in response to a chemical stimulus. The chemotactic polymersomes can be targeted in vivo to a location of therapeutic interest with high specificity and selectivity. The present invention also provides related pharmaceutical compositions and therapeutic methods.

Claims (20)

1. A method comprising

administering a chemotactic, drug-containing polymersome to a subject; and

delivering said chemotactic, drug-containing polymersome to the brain tissue of said subject by transcytosis of said chemotactic, drug-containing polymersome across the blood-brain barrier of said subject; wherein said chemotactic, drug-containing polymersome comprises:

(a) a polymersome that comprises a targeting moiety on its external surface, wherein the targeting moiety is adapted to enable the polymersome to cross the blood-brain barrier;

(b) an enzyme encapsulated within the polymersome, wherein the enzyme comprises glucose oxidase; and

(c) a drug encapsulated within the polymersome;

wherein:

(i) the polymersome is permeable to a signalling molecule that is a substrate for the enzyme, wherein the signalling molecule is glucose;

(ii) the enzyme is capable of converting the signalling molecule into one or more product molecules;

(iii) the polymersome is permeable to the one or more product molecules;

(iv) the permeability to the one or more product molecules of a first region of the polymersome is greater than the permeability to the one or more product molecules of a second region of the polymersome, the second region being diametrically opposed to the first region; and

(v) the first region of the polymersome comprises a first polymer and the second region of the polymersome comprises a second polymer, the second polymer being different from the first polymer.

2. The method of claim 1 , wherein the molar ratio of the first polymer to the second polymer is less than 1:1.

3. The method of claim 2 , wherein the molar ratio of the first polymer to the second polymer is less than 1:4.

4. The method of claim 1 , wherein the targeting moiety is an antibody or antibody fragment, a peptide, an aptamer, a small molecule, a vitamin or a carbohydrate that is attached to the external surface of the polymersome.

5. The method of claim 1 , wherein the targeting moiety is a pendant group of a polymer comprised by the polymersome.

6. The method of claim 1 , wherein the targeting moiety targets the LRP-1 receptor.

7. The method of claim 6 , wherein the targeting moiety is a peptide comprising the sequence TFFYGGSRGKRNNFKTEEY (SEQ ID No. 1).

8. The method of claim 1 , wherein the enzyme comprises glucose oxidase in combination with catalase.

9. The method of claim 1 , wherein the drug is selected from a neuroprotectants, immunomodulatory drugs, NSAIDs, corticosteroids, DMARDs, immunosuppressants, TNF-alpha inhibitors and anti-cancer drugs.

Assignments (2)
CHANGE OF NAME Recorded Nov 20, 2020
From: UCL BUSINESS PLC
To: UCL BUSINESS LTD
Reel/Frame 054490/0278 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2019
From: BATTAGLIA, GIUSEPPE
To: UCL BUSINESS PLC
Reel/Frame 049544/0316 →
Priority Claims (1)
GB 1603296.3 · Feb 25, 2016 · national
Continuity (1)
Related Publication 20190046445A1 · Feb 14, 2019